Tirzepatide vs Mod GRF 1-29

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Full details →

Mod GRF 1-29

Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.

Full details →

Side-by-Side Comparison

AspectTirzepatideMod GRF 1-29
MechanismActivates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity.
Typical DosageStart at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects.
AdministrationSubcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version.
Side EffectsSimilar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention.
Best For

What They Have in Common

Both Tirzepatide and Mod GRF 1-29 are commonly used for:

Key Differences

Ready to Learn More?